Ranbaxy announced on 4 October 2013 that Ohm had received a copy from the US Food and Drug Administration (FDA) of its Establishment Inspection Report (EIR) for its December 2012 inspection. FDA issues an EIR to a company or an establishment that was subject of an FDA or FDA-contracted inspection when the regulator determines the inspection to be ‘closed’.

This is great news for Ranbaxy, owned by Japan-based Daiichi Sankyo, as it would allow the company to continue supplying from this site. This is vital at the moment when Ranbaxy’s three India-based facilities – Paonta Sahib, Dewas and Mohali – are all under FDA import alerts and banned from supplying drugs to the US.

Ohm had been under investigation since 2009 when FDA first issued a warning letter to the site concerning good manufacturing practice violations. The facility was also part of FDA’s consent decree, which Ranbaxy signed in January 2012 [1]. However, this clearance from FDA means that Ranbaxy could potentially move some of its pending applications to Ohm from its Mohali manufacturing site to avoid delays in product launches.

Related articles

India’s drug regulator finds no problem at Ranbaxy sites

Ranbaxy receives another import ban from FDA

Reference

1.  GaBI Online - Generics and Biosimilars Initiative. Ranbaxy consent decree with FDA submitted to court [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 8]. Available from: www.gabionline.net/Generics/News/Ranbaxy-consent-decree-with-FDA-submitted-to-court

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.